TAP1 and cancer: The levels of cancer cell PD-L1 protein were lower in cases with TAP1/2 downregulation in cohort #1, but no difference was seen in cohorts #2 and #4, suggesting independence of TAP1/2 loss from other adaptive immune evasion mechanisms (Supplementary Fig.S1D).